pocketful logo
Beta Drugs Ltd logo

Beta Drugs Ltd

NSE: BETA BSE: 535022

₹1323.70

(0.55%)

Thu, 23 Apr 2026, 02:39 pm

mtf coin illustrationMTF 5x

Beta Drugs Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    1341.82

  • Net Profit

    42.42

  • P/B

    9.76

  • Sector P/E

    32.34

  • P/E

    45.35

  • EV/EBITDA

    25.04

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    20.25

  • ROCE (Industry)

    20.84

  • RONW (Industry)

    17.81

  • ROE

    23.95

  • ROCE

    24.48

  • Debt/Equity

    0.43

  • EPS (TTM)

    43.10

  • Dividend Yield

    0

  • Book Value

    224.93

  • Interest Cover

    9.15

Analysis

all

thumbs up icon

Pros

  • Beta Drugs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Beta Drugs is profitable, therefore cash runway is not a concern.
  • Beta Drugs is profitable, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (42.2%, greater than 20% of total debt).
  • Debt is covered by short term assets, assets are 2.8x debt.
thumbs up icon

Cons

  • Unable to evaluate Beta Drugs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Beta Drugs's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • High level of physical assets or inventory.
  • Beta Drugs is not covered by any analysts.
  • Beta Drugs has significant price volatility in the past 3 months.

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters64.9066.7366.7366.7366.73
FII1.140.910.900.901.15
DII1.900000
Public32.0732.3632.3632.3632.11
Government00000

Read More

Technical Analysis

RSI

52.92

MACD

38.49

50 DMA

1217.95

200 DMA

1590.54

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic1617.031381.431285.371145.831049.77910.23674.63
Fibonacci1381.431291.431235.831145.831055.831000.23910.23
Camarilla1254.091232.491210.901145.831167.701146.111124.51

Pivots Level: Classic

R3

+471.20

1617.03

R2

+235.60

1381.43

R1

+139.53

1285.37

1145.83
1145.83
Pivot Point
LTP: 1328.30

S1

-96.07

1049.77

S2

-235.60

910.23

S3

-471.20

674.63

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    1347.25

  • 20-EMA

    1320.34

  • 30-EMA

    1299.58

  • 50-EMA

    1303.10

  • 100-EMA

    1385.08

  • 200-EMA

    1504.43

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
12 Jan 2026egm
06 Nov 2025board-meetingsHalf Yearly Results
03 Sept 2025agm
21 Mar 2025bonus1:20 Bonus Issue of Equity Shares26 Mar 2025
27 Nov 2024egm
19 Oct 2024egm
31 Aug 2024agm
01 Sept 2023agm
30 Aug 2022agm
31 Aug 2021agm

Read More

Peer Comparison

Beta Drugs Ltd logo

Beta Drugs Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Lupin Ltd logo

Lupin Ltd

Read More

Beta Drugs Ltd About

Beta Drugs manufacturing, and marketing of oncology (anti-cancer) products including tablets, capsules, and injections

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

2005

Headquarters

CEO

Rahul Batra

Employees

Contact

Website icon

Website

http://www.betadrugslimited.com

Email icon

Email

info@betadrugslimited.com

Phone icon

Phone

91-1795-236196

Location icon

Location

Village Nandpur, , Baddi, Himachal Pradesh, 174101

Read More

Beta Drugs Ltd Company History

YearHistory
2015
  • ISO: 9001:2008 Certification for manufacturing and supply of Pharmaceutical products.
  • Certificate of Good Manufacturing Practice from Health and Family Welfare Department, Himachal Pradesh.
2016
  • Certificate of Good Manufacturing Practice from Republic of Kenya.
2017
  • Conversion of Company into Public Limited Company.
  • The name of the Company was changed to Beta Drugs Limited.
2024
  • The Company Earns Forbes Asia Best Under a Billion 2024 Award for Third Consecutive Year.
2025
  • The Company has issued Bonus Shares in the Ratio of 1:20.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
NEERAJ BATRASell185115168613 Nov 2025
AIRAVAT CAPITAL TRUST IIBuy155925168613 Nov 2025
BATRA VIJAY KUMARBuy5040084.9501 Sept 2020
ONKAR SINGHBuy8720096.0324 Jul 2020
ADESH VENTURES LLPSell10800095.5224 Jul 2020
BATRA VIJAY KUMARBuy4880073.2529 Nov 2018
VALUEWORTH CAPITAL MANAGEMENT PVT LTDSell5200070.0629 Oct 2018
SACHIN KASERABuy504007029 Oct 2018
VORA FINANCIAL SERVICES PRIVATELIMITEDSell5120090.1423 Jul 2018
SHATRUNJAY INVESTMENTSSell4960096.2717 Oct 2017

Read More

Beta Drugs Ltd News

Beta Drugs Achieves Key Regulatory Milestones

Beta Drugs Limited secures GMP inspection approval in Azerbaijan and receives first generic product registrations in Philippines, expanding CIS and Southeast Asian market access.

22 Apr 2026

companies

Beta Drugs Gets Philippines Product Registration

Beta Drugs Limited secures product registration for two generic brands in the Philippines, with additional approvals anticipated in the near future.

22 Apr 2026

companies

Beta Drugs Acquires 66% Stake in Nivian Lifesciences

Beta Drugs announces ₹69.4 crore acquisition of 66.09% stake in IVF specialist Nivian Lifesciences, marking entry into women's health segment. Stock jumps 4% on announcement.

12 Jan 2026

co actions results

Beta Drugs to Acquire 66.09% Stake in Nivian Life

Beta Drugs announces acquisition of majority 66.09% stake in Nivian Life Sciences for ₹694 million, marking significant expansion in pharmaceutical sector through strategic investment.

09 Jan 2026

co actions results

Beta Drugs Receives Approval to Migrate from SME Platform to Main Board Listing

Beta Drugs has received approval to list its equity shares on the main board after migrating from the SME Emerge platform. This migration represents a significant milestone for the company, allowing it to access broader investor base and enhanced market visibility.

21 Nov 2025

stock

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800